Edition:
United States

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

158.03USD
14 Dec 2017
Change (% chg)

$-6.62 (-4.02%)
Prev Close
$164.65
Open
$164.36
Day's High
$164.36
Day's Low
$155.43
Volume
343,166
Avg. Vol
273,878
52-wk High
$173.28
52-wk Low
$44.58

Select another date:

Thu, Dec 7 2017

Sage shares surge as depression drug succeeds in mid-stage trial

Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.

UPDATE 3-Sage shares surge as depression drug succeeds in mid-stage trial

* Shares surge as much as 85 pct (Adds details on drug's mechanism, analyst comment, updates shares)

Sage's depression drug succeeds in mid-stage study

Dec 7 Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

BRIEF-Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share

* SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Sage Therapeutics announces proposed public offering of common stock

* Sage Therapeutics announces proposed public offering of common stock

Sage soars as postpartum depression drug moves closer to approval

Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.

UPDATE 3-Sage soars as postpartum depression drug moves closer to approval

* Shares zoom about 55 pct to all-time high (Adds details from conference call, analyst comments and background on disease space)

REFILE-Sage Therapeutics postpartum depression drug meets main goal

Nov 9 Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies.

BRIEF-Sage Therapeutics announces Brexanolone achieves primary endpoints

* Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression

BRIEF-Sage Therapeutics announces qtrly loss per share $1.97‍​

* Sage Therapeutics announces third quarter 2017 financial results and provides pipeline update

Select another date: